Published in Semin Radiat Oncol on January 01, 2013
Pathogenetic mechanisms in gastric cancer. World J Gastroenterol (2014) 0.97
Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma. J Transl Med (2014) 0.91
The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China. Oncotarget (2016) 0.86
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS One (2016) 0.85
SOD2 rs4880 CT/CC genotype predicts poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy. Am J Transl Res (2015) 0.83
Diet and upper gastrointestinal cancers: in search of dark matter. Clin Gastroenterol Hepatol (2013) 0.79
Rare Presentation of Gastroesophageal Carcinoma with Rectal Metastasis: A Case Report. Am J Case Rep (2016) 0.79
Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci (2014) 0.79
Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer (2015) 0.78
Clinical Outcomes of Endoscopic Submucosal Dissection for Adenocarcinoma of the Esophagogastric Junction. Dig Dis Sci (2016) 0.77
CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma. Oncotarget (2016) 0.77
Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Radiat Oncol (2014) 0.77
The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. Cell Mol Gastroenterol Hepatol (2016) 0.76
Survival benefit of surgery with radiotherapy vs surgery alone to patients with T2-3N0M0 stage esophageal adenocarcinoma. Oncotarget (2016) 0.76
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction. Am J Med Sci (2015) 0.76
Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomark Res (2016) 0.76
Within-pair differences of DNA methylation levels between monozygotic twins are different between male and female pairs. BMC Med Genomics (2016) 0.75
GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer. Sci Rep (2017) 0.75
Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. Medicine (Baltimore) (2015) 0.75
Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas. Oncotarget (2016) 0.75
A Rare Case of Esophageal Adenocarcinoma with Urinary Bladder Metastasis. Case Rep Gastrointest Med (2017) 0.75
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Med (2016) 0.75
Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma. Semin Oncol (2015) 0.75
Should Splenic Hilar Lymph Nodes be Dissected for Siewert Type II and III Esophagogastric Junction Carcinoma Based on Tumor Diameter?: A Retrospective Database Analysis. Medicine (Baltimore) (2016) 0.75
Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction. World J Gastroenterol (2015) 0.75
Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. Gastric Cancer (2016) 0.75
Molecular classification of esophagogastric junction carcinoma correlated with prognosis. Onco Targets Ther (2017) 0.75
A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. Exp Mol Med (2017) 0.75
Significance of 18F-Fluorodeoxyglucose Uptake at the Gastroesophageal Junction: Comparison of PET to Esophagogastroduodenoscopy. Dig Dis Sci (2014) 0.75
Expression of serum- and glucocorticoid-regulated kinase 1 and its association with clinicopathological factors and the survival of patients with adenocarcinoma of the esophagogastric junction. Oncol Lett (2017) 0.75
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA (1991) 11.53
Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg (1998) 4.95
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ (2010) 4.92
Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1998) 3.66
Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA (2010) 3.37
Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med (1999) 3.31
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22
Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol (2007) 3.18
Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst (1999) 3.13
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst (2003) 3.07
Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst (2006) 2.97
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol (2000) 2.97
The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA (1995) 2.68
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 2.59
The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer (2000) 2.58
Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology (2009) 2.55
Helicobacter infection and gastric neoplasia. J Pathol (2006) 2.54
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control (2001) 2.31
Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut (2007) 2.28
Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2001) 2.13
Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology (2010) 1.91
Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev (2008) 1.89
Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut (2005) 1.74
Epidemiology of esophageal adenocarcinoma. J Surg Oncol (2005) 1.69
Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol (2007) 1.63
Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer (2009) 1.61
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst (2010) 1.60
Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control (1993) 1.60
Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Nutr Cancer (1997) 1.59
A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Ann Oncol (2011) 1.57
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Increasing incidence of carcinoma of the gastric cardia in Sweden from 1970 to 1985. Br J Surg (1993) 1.40
Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. J Natl Cancer Inst (2004) 1.38
Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. Cancer Epidemiol Biomarkers Prev (2010) 1.19
Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut (2011) 1.18
Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden. Nutr Cancer (2006) 1.15
A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut (2011) 1.14
Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev (2008) 1.10
Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut (2010) 1.04
Monitoring the changing pattern of esophago-gastric cancer: data from a UK regional cancer registry. Cancer Causes Control (2001) 1.03
Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis. Epidemiology (2011) 1.03
Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer (2010) 1.03
Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila) (2011) 1.00
Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. Am J Epidemiol (2011) 0.99
Pathology of the gastroesophageal junction. Semin Diagn Pathol (2005) 0.91
Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several? Semin Oncol (2004) 0.86
Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002. Can J Gastroenterol (2006) 0.85
An evaluation of the use of oral bisphosphonates and risk of esophageal cancer. Ann Pharmacother (2012) 0.85
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27
Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol (2007) 3.18
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst (2003) 3.07
Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2007) 2.39
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Central adiposity and risk of Barrett's esophagus. Gastroenterology (2007) 2.20
Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst (2006) 2.08
Racial disparities among patients with lung cancer who were recommended operative therapy. Arch Surg (2009) 2.02
A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2006) 1.98
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89
Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg (2010) 1.68
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst (2010) 1.60
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Occupational exposures and risks of liver cancer among Shanghai female textile workers--a case-cohort study. Int J Epidemiol (2005) 1.50
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev (2016) 1.38
Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev (2005) 1.31
Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. Cancer Causes Control (2002) 1.31
Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) (2013) 1.31
Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol (2012) 1.30
Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control (2004) 1.30
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29
Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology (2012) 1.28
Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J Natl Cancer Inst (2013) 1.25
Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One (2013) 1.23
Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol (2005) 1.21
A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila) (2012) 1.21
Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut (2011) 1.18
Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) (2010) 1.18
Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.18
Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals. Gastroenterology (2010) 1.18
Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer (2008) 1.17
Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.17
Genetic variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal cancers in Caucasian populations. Eur J Cancer Prev (2012) 1.17
Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol (2009) 1.14
Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992-2002. Am J Epidemiol (2005) 1.13
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One (2013) 1.08
CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev (2009) 1.07
Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev (2003) 1.02
Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev (2003) 1.02
Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila) (2011) 1.00
Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. Int J Cancer (2014) 0.99
Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst (2003) 0.99
NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet (2013) 0.98
GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev (2007) 0.98
The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol (2012) 0.95
Survival differences by race in nasopharyngeal carcinoma. Am J Epidemiol (2006) 0.94
Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants. PLoS One (2012) 0.94
Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev (2004) 0.94
Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol (2012) 0.93
Vegetable and fruit intakes and risk of Barrett's esophagus in men and women. Am J Clin Nutr (2009) 0.93
Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2012) 0.92
Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus. Cancer Epidemiol Biomarkers Prev (2005) 0.90
Occupation and risk of esophageal and gastric cardia adenocarcinoma. Am J Ind Med (2002) 0.90
Alcohol dehydrogenase 3 and risk of esophageal and gastric adenocarcinomas. Cancer Causes Control (2007) 0.89
Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutr Cancer (2008) 0.89
Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view. PLoS Comput Biol (2011) 0.89
Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2007) 0.89
Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer. Nutr Cancer (2013) 0.88
Serum selenium, genetic variation in selenoenzymes, and risk of colorectal cancer: primary analysis from the Women's Health Initiative Observational Study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 0.88
Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control (2008) 0.88
Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Cancer Epidemiol Biomarkers Prev (2006) 0.87
History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2011) 0.87
A population-based study of glutathione S-transferase M1, T1 and P1 genotypes and risk for lung cancer. Lung Cancer (2003) 0.86
Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. Cancer Causes Control (2014) 0.85
Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium. Eur J Epidemiol (2013) 0.84
Recreational physical activity and risk of papillary thyroid cancer among women in the California Teachers Study. Cancer Epidemiol (2012) 0.83
Possible association between a genetic polymorphism at 8q24 and risk of upper gastrointestinal cancer. Eur J Cancer Prev (2011) 0.82
Wood dust exposure and risk of lung cancer. Occup Environ Med (2010) 0.81
Gastric fluid bile concentrations and risk of Barrett's esophagus. Interact Cardiovasc Thorac Surg (2007) 0.79
Diet and upper gastrointestinal cancers: in search of dark matter. Clin Gastroenterol Hepatol (2013) 0.79
Risks of biliary tract cancer and occupational exposures among Shanghai women textile workers: a case-cohort study. Am J Ind Med (2006) 0.78
MUC2 is a highly specific marker of goblet cell metaplasia in the distal esophagus and gastroesophageal junction. Am J Surg Pathol (2011) 0.78
Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. Cancer Epidemiol Biomarkers Prev (2013) 0.78
Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers. Clin Diagn Lab Immunol (2004) 0.78
IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer (2009) 0.78
Specialty supplement use and biologic measures of oxidative stress and DNA damage. Cancer Epidemiol Biomarkers Prev (2013) 0.77
Recent physical activity in relation to DNA damage and repair using the comet assay. J Phys Act Health (2014) 0.77
Quantification of population benefit in evaluation of biomarkers: practical implications for disease detection and prevention. BMC Med Inform Decis Mak (2014) 0.77
Histologic Features Associated With Columnar-lined Esophagus in Distal Esophageal and Gastroesophageal Junction (GEJ) Biopsies From GERD Patients: A Community-based Population Study. Am J Surg Pathol (2016) 0.76